Transforming Aneurysm Treatment: Celebrating 15 Years of the WEB™ Device

Celebrating 15 Years of the WEB™ Device

Terumo Neuro, a renowned name in neurovascular innovation and a subsidiary of Terumo Corporation, is proud to celebrate the 15th anniversary of its revolutionary WEB™ Aneurysm Embolization System. This device has fundamentally changed the approach to treating wide-neck bifurcation aneurysms, offering a single, effective solution that has been embraced by physicians around the world.

A Groundbreaking Development

Launched commercially in October 2010 after receiving its CE Mark in Europe, the WEB device was first implanted by Professor Joachim Klisch in Germany. Since then, it has been regarded as a game-changing tool in the field of neurovascular care. As of 2025, over 25,000 WEB devices have been implanted globally, highlighting its significant impact on the medical community and patient outcomes.

The WEB device is celebrated not only for its innovative design but also for its clinical efficacy. Supported by seven Global Good Clinical Practice (GCP) studies and over 200 peer-reviewed publications, the device provides a clinically proven approach to treating aneurysms safely and effectively. The simplicity of the One and Done concept—implementing a single device to address complex issues—enhances the treatment process, reducing the need for multiple devices and extensive procedures.

Significant Milestones and Success Rates

Carsten Schroeder, the President and CEO of Terumo Neuro, remarked on this impressive milestone, stating, "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes."

The safety and reliability of the WEB device is further underscored by clinical data demonstrating zero rebleeds recorded in treated aneurysms. In follow-up studies, including the WEB-IT and WEBCAST trials, the device showed sustained safety and efficacy, with 0% device-related morbidity or mortality reported in patients over a five-year period. This comprehensive data significantly supports the device's long-term use in managing aneurysms.

The Future of Neurovascular Care

This anniversary not only highlights the success of the WEB device but also sets the stage for its future developments. The recent introduction of the WEB 17 system, a smaller device designed for treating smaller aneurysms, has refined the treatment options available to physicians and patients alike. This advancement demonstrates Terumo Neuro's commitment to continually evolving its technology to fit wide-ranging patient needs.

With a legacy of innovation, the WEB device remains the preferred choice for medical professionals treating wide-neck bifurcation aneurysms. The ongoing evolution of the device aligns with Terumo's mission to create and deliver transformative innovations in neuroendovascular treatment.

About Terumo Neuro

Founded in 1997 and rebranded from MicroVention, Inc. after its acquisition by Terumo Corporation in 2006, Terumo Neuro has grown to offer over thirty products for managing cerebral aneurysms, ischemic stroke, and neurovascular malformations. Based in Aliso Viejo, California, Terumo Neuro operates in more than seventy countries, exemplifying its global reach and influence in the medical field. The company's commitment to redefining possibilities in neurovascular care continues to shape the landscape of medical technology.

For more information about the WEB device and other products from Terumo Neuro, please visit Terumo Neuro's official website.